Blokatory retseptorov angiotenzina i ingibitory angiotenzinprevrashchayushchego fermenta: poedinok dvukh liderov farmakoterapii serdechno-sosudistykh zabolevaniy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article deals with current issues of pharmacotherapy of cardiovascular diseases, which are based on dysfunction of the renin-angiotensin-aldosterone system. The efficacy and safety of two major classes of drug therapy for cardiovascular diseases -sartans and angiotensin converting enzyme inhibitors - are compared; evidence-based data on both classes of drugs are presented.

全文:

受限制的访问

参考

  1. Davis JO. The second Volhard Lecture: the use of blocking agents to define the functions of the renin-angiotensin system. Clin Sci Mol Med 19 75;2 (Suppl.):3 -14.
  2. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978;298(18):991-95.
  3. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patients outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114(25):2850-70.
  4. Кукес В.Г., Сычев Д.А., Стародубцев А.К., Раменская Г.В., Максимов М.Л. и др. Клиническая фармакология. Учебник для студентов медицинских вузов. М., 2009. 1056 с.
  5. Максимов М.Л. Клинико-фармакологические подходы к регуляции активности ренин-ангиотензин-альдостероновой системы у больных артериальной гипертонией и хронической болезнью почек. Дисс. докт. мед. наук. М., 2011.
  6. Остроумова О.Д., Максимов М.Л. Место ингибиторов ангиотензинпревращающего фермента в лечении артериальной гипертонии у различных групп пациентов // Кардиоваск. терапия и профилактика 2010. № 9(7). С. 90-6.
  7. Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. Хроническая сердечная недостаточность. М., 2010.
  8. Скворцов А.А, Мареев В.Ю., Беленков Ю.Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН // Сердце 2008. № 5. С. 275-83.
  9. Беленков Ю.Н. Мареев В.Ю. Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М., 2006.
  10. Остроумова О.Д., Максимов М.Л., Щукина Г.Н., Шорикова Е.Г. Антагонисты рецепторов к ангиотензину II в 2010: что нового? // Системные гипертензии 2011. № 1. C. 12-5.
  11. Максимов М.Л., Дралова О.В., Стародубцев А.К. Антагонисты АТ1-рецепторов ангиотензина II, ингибиторы ангиотензинпревращающего фермента в регуляции гемодинамики и активности ренин-ангиотензин-альдостероновой системы. Фокус на органопротективные эффекты // Кардиоваск. терапия и профилактика 2010. № 9(2). С. 115-24.
  12. КобалаваЖ.Д., КотовскаяЮ.В., Моисеев В.С. Артериальная гипертензия. Ключи к диагностике. M., 2009.
  13. Кобалава Ж.Д., Шаварова Е.К. Антагонисты рецепторов к ангиотензину II в кардиологической практике: современный взгляд на проблему // РМЖ 2008. №11. C. 1609-16.
  14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
  15. Lindholm LH, Ibsen H, Dahlof B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311): 1004-10.
  16. Mochizuki S, Dahlof B, Taniguchi I, et al, for the JIKEI HEART Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-39.
  17. Parving HH, Lenhert H, et al. The effects of irbesartan on the development of diabetic nephropathy in patients with types 2 diabetes. N Engl J Med 2001;345(12):870-78.
  18. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
  19. Viberti G, Wheeldom NM. MicroAlbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type II diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106(6):672-78.
  20. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2001 ;345( 12):851 -60.
  21. Schrader J, et al. Morbidity and Mortality after Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36(2):1218-26.
  22. Julius S, Kjeldsen SE, Weber M, et al. Outcome in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004;363(9426):2022-31.
  23. The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010;362:1477-90.
  24. Hollenberg NK, et al. The Diovan reduction of Proteinuria Drop study: Albuminuria response to high doses of Valsartan in Type 2 Diabetes Mellitus. Circulation 2006;114:11-61.
  25. Национальные рекомендации по диагностике и лечению артериальной гипертензии ВНОК. 4-й пересмотр, 2010.
  26. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared to captopril on mortality in patients with symptomatic heart failure; randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215): 1582-87.
  27. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Lancet 2002;360(9335):752-60.
  28. Pfeffer MA, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
  29. Cohn JN, Tognoni G. Valsartan Heart FailureTrial Investigator. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23): 1667-75.
  30. Granger CB, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 2003;362:772-76.
  31. Baker WL, Coleman CI, et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease. Ann Intern Med 2009;151: 861-71.
  32. Matchar DB, McCory DC, et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008;148:16-29.
  33. Kunz R, Friedrich C, et al. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008;148:30-48.
  34. Verdeccia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005;26:2381-86.
  35. Pitt B, ONeill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Amer J Cardiology 2001;87:1058-63.
  36. Pitt B, Pfeffer MA, Domanski M, et al. Prevention of events with angiotensine-converting enzyme inhibition: results of the PEACE study. New Engl J Med 2004;35:2058-117.
  37. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
  38. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665, doi: 10.1136/ bmj.b1665.
  39. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15): 1547-59.
  40. Wang L, Huang Xin-sheng, et al. Effects of angiotensin blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study. J First Mil Med Univ 2005;25(8).

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##